Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…Abstract Number: 2677 • 2018 ACR/ARHP Annual Meeting
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Background/Purpose: SLE-related organ damage is associated with increased morbidity. The comorbidity burden of SLE can involve various organ systems and may include pain, fatigue, difficulty…Abstract Number: 101 • 2018 ACR/ARHP Annual Meeting
Regulation of Monocyte Function By Epstein Barr Virus Interleukin-10 (vIL10) in Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…Abstract Number: 738 • 2018 ACR/ARHP Annual Meeting
Two Clinical Phenotypes of Chinese SLE-PAH Patients
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE), which is the most common underlying disease of CTD associated PAH.…Abstract Number: 970 • 2018 ACR/ARHP Annual Meeting
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the Europe and…Abstract Number: 1671 • 2018 ACR/ARHP Annual Meeting
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: The Physician Global Assessment (PGA) is a frequently-used outcome measure in Systemic Lupus Erythematosus (SLE). The PGA is intended to encapsulate the physician’s judgement…Abstract Number: 1678 • 2018 ACR/ARHP Annual Meeting
How Consistently Do Publications Define SLE? a Systematic Review
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous. ACR and/or SLICC classification criteria provide homogeneous populations for research purposes, but studies differ in selection and…Abstract Number: 1695 • 2018 ACR/ARHP Annual Meeting
Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients
Background/Purpose: Approximately 20% of patients with Systemic Lupus Erythematosus (SLE) begin their illness in childhood or adolescence. These patients are described with a phenotype of…Abstract Number: 687 • 2017 ACR/ARHP Annual Meeting
Homocysteine Levels Are Independently Associated with Damage Accrual in Systemic Lupus Erythematosus Patients (SLE)
Background/Purpose: Homocysteine level is a predictor of the occurrence of cardiovascular diseases, however, its role as a predictor of damage in SLE has not been…Abstract Number: 1646 • 2017 ACR/ARHP Annual Meeting
Cardiovascular disease in Systemic Lupus Erythematosus. The road to hell is paved with good intentions
Background/Purpose: Accurate diagnosis of cardiovascular involvement in systemic lupus erythematosus (SLE) remains challenging, because echocardiography (echo), the cornerstone tool used, has serious limitations. We hypothesized…Abstract Number: 1654 • 2017 ACR/ARHP Annual Meeting
Predictive Factors According to Type of Infection in Systemic Lupus Erythematosus Patients: Data from a Multi-Ethnic, Multi-National, Latin-American Cohort
Background/Purpose: While infections are a one of the main causes of mortality in systemic lupus erythematosus (SLE), the type of infections and the factors predisposing…Abstract Number: 2610 • 2017 ACR/ARHP Annual Meeting
Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus
Background/Purpose: Tuberculosis (TB) has been reported to occur at a higher rate in SLE patients than in the general population. As a result, most clinical…Abstract Number: 2619 • 2017 ACR/ARHP Annual Meeting
Hemophagocytic Syndrome in Patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune systemic rheumatic disease that, in our area, presents hematologic manifestations in approximately 70% of cases1. Some of…Abstract Number: 2627 • 2017 ACR/ARHP Annual Meeting
Characterization of Emergency Department Visits in an Urban Underserved Lupus Cohort
Background/Purpose: SLE patients frequently utilize the Emergency Department (ED), impacting the cost of care and quality of life. We performed a retrospective analysis of ED…Abstract Number: 2629 • 2017 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients Not Complaining Raynaud’s Phenomenon Display Lower Skin Blood Perfusion Than Healthy Subjects
Background/Purpose: A clinical feature of patients with primary Raynaud's phenomenon (PRP) is the presence of low skin blood perfusion (BP) at the level of hands…
- 1
- 2
- 3
- …
- 7
- Next Page »